5 completed, 3 recruiting, 1 active not recruiting, 1 suspended. 6 Phase 1, 3 Phase 2, 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Recruiting 2, Suspended 1 |
| Phase 2 | 3 | Active not recruiting 1, Recruiting 1, Suspended 1 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow KYMRIAH: new trials by email Literature Review of KYMRIAH trials Research Report on KYMRIAH
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | Nathan Denlinger | 18 | 2026-12-01 | 2026-10-09 |
| Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies CD22CART infusion, Tisagenlecleucel - Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Stanford University | 28 | 2024-05-13 | 2026-09-01 |
| Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 2 | Recruiting | SWOG Cancer Research Network | 396 | 2023-06-12 | 2026-10-15 |
| Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study Duvelisib, Tisagenlecleucel - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Early Phase 1 | Completed | Emory University | 4 | 2022-01-13 | 2025-01-20 |
| Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy Efineptakin alfa, Tisagenlecleucel, Axicabtagene ciloleucel - Refractory Diffuse Large B-cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | NeoImmuneTech | 17 | 2021-07-29 | 2026-08-10 |
| Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL E7777, Fludarabine, Cyclophosphamide - DLBCL, Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | Suspended | Masonic Cancer Center, University of Minnesota | 30 | 2021-06-09 | 2026-11-04 |
| CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI) KYMRIAH, YESCARTA - Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL) | Completed | Novartis Pharmaceuticals | 273 | 2020-12-09 | 2022-07-01 | |
| Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia Tisagenlecleucel, Blinatumomab, Inotuzumab - Acute Lymphoblastic Leukemia | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2020-06-05 | 2020-07-09 | |
| Tisagenlecleucel In Primary CNS Lymphoma Tisagenlecleucel - Primary CNS Lymphoma, Refractory Primary CNS Lymphoma | Phase 1 | Completed | Matthew J. Frigault, M.D. | 13 | 2019-01-01 | 2026-01-09 |
| MT2017-45: CAR-T Cell Therapy for Heme Malignancies KYMRIAH, YESCARTA, Fludarabine 30mg/m2 4 doses - Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | Phase 2 | Active not recruiting | Masonic Cancer Center, University of Minnesota | 150 | 2018-12-18 | 2026-01-23 |
| CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis - Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 26 | 2015-12-16 | 2022-06-30 |
Lymphoma, Large B-Cell, Diffuse (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Leukemia (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Neoplasm, Residual (1)
Masonic Cancer Center, University of Minnesota (2) · Novartis Pharmaceuticals (2) · Emory University (1) · M.D. Anderson Cancer Center (1) · Matthew J. Frigault, M.D. (1) · Nathan Denlinger (1) · NeoImmuneTech (1) · SWOG Cancer Research Network (1) · Stanford University (1)
United States (10)
Brian T Hess (1) · Edmund K Waller, MD, PhD (1) · John DiPersio, M.D. (1) · Matthew J. Frigault, MD (1) · Nathan Denlinger, DO (1) · Partow Kebriaei (1) · Veronika Bachanova, MD (1) · Veronika Bachanova, MD, PhD (1)
P30CA138292 (1), U10CA180888 (1)